Is Fampridine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 1 valid registration of Fampridine, including FAMPYRA 10MG Prolonged-release tablet (10 mg, Prolonged-release tablet, SAR 1133.90).

Is Fampridine authorised in the European Union?

EMA lists 2 centrally authorised medicines containing Fampridine: Fampyra, Fampridine Accord.

Active substance

Fampridine

SFDA 1
EMA 2
Health Canada 3

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
FAMPYRA 10MG Prolonged-release tablet	10 mg	Prolonged-release tablet · Oral use	56 Tablet Container	SAR 1133.90	NCE · Prescription	Acorda Therapeutics lreland Limited	Valid

Indications — CHI Daman Drug Formulary

MULTIPLE SCLEROSIS

EMA European Union — centrally authorised medicines

Fampyra Merz Therapeutics GmbH · Authorised · authorised 20 Jul 2011 · ATC N07XX07

Therapeutic indication (EMA)

Fampyra is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (Expanded Disability Status Scale 4-7).

Fampridine Accord Accord Healthcare S.L.U. · Authorised · authorised 24 Sep 2020 · ATC N07XX07

Therapeutic indication (EMA)

Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7).

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
FAMPYRA	02379910	10 MG	TABLET (EXTENDED-RELEASE) · ORAL	MERZ THERAPEUTICS GMBH
PMS-FAMPRIDINE	02496216	10 MG	TABLET (EXTENDED-RELEASE) · ORAL	PHARMASCIENCE INC
TARO-FAMPRIDINE	02482398	10 MG	TABLET (EXTENDED-RELEASE) · ORAL	TARO PHARMACEUTICALS INC

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.